Skip to content

Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy

Erythromycin Versus Neomycin Treatment for Overt Hepatic Encephalopathy: a Double-blind, Randomised, Controlled Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01097811
Enrollment
20
Registered
2010-04-02
Start date
2008-06-30
Completion date
2010-12-31
Last updated
2010-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Encephalopathy, Hypertension, Portal, Liver Cirrhosis

Keywords

Hepatic Encephalopathy, Hypertension, Portal, Liver Cirrhosis, Bacterial Overgrowth Syndrome

Brief summary

Comparison between the efficacy of two different antibiotics in patients with overt hepatic encephalopathy. The study is randomized, controlled and double-blinded.

Interventions

DRUGErythromycin

250 mg orally q.i.d.

1 g orally q.i.d.

Sponsors

Biophisics Department of Biosciences Institute - Unesp
CollaboratorUNKNOWN
Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
UPECLIN HC FM Botucatu Unesp
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Hepatic cirrhosis or portal hypertension * Hepatic Encephalopathy

Exclusion criteria

* Acute liver failure * Neuropsychiatric diseases * Inflammatory bowel diseases * Intestinal obstruction * Shock * Renal insufficiency * Alcoholic hepatitis * Alcohol abuse * Antibiotic premedication

Design outcomes

Primary

MeasureTime frameDescription
Recovery of hepatic encephalopathythree yearscomparison of efficacy between two drugs for the treatment of hepatic encephalopathy

Secondary

MeasureTime frameDescription
length of hospitalization caused by hepatic encephalopathythree yearscomparison of efficacy between two drugs for reducing the length of hospitalization during treatment of hepatic encephalopathy

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026